Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMNANT study (Relapse from MRD Negativity as Indication for Treatment)
2019-004401-27Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bortezomib, lenalidomide, dexamethasone, daratumumab and carfilzomib in multiple myeloma (MM), sponsored by Oslo University Hospital. Primary endpoint: Primary Endpoint Part 1. Started Dec 2019; status: active.
02
Drugs
bortezomiblenalidomidedexamethasonedaratumumabcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-004401-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004401-27.